Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ADA | P00813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727054 | 1.00 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL14782094 | 0.84 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL733121 | 0.84 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL474846 | 0.84 | ADORA2A (0.53) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL12154572 | 0.84 | ADORA2A (0.53) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL12150880 | 0.84 | ADORA2A (0.53) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL12031227 | 0.84 | ADORA2A (0.53) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL6388400 | 0.83 | ADORA2A (0.46) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL12194688 | 0.83 | ADORA1 (0.74) | ADORA3ADORA1ADORA2AADORA2BALOX15 | |
| SCHEMBL21136562 | 0.83 | ADORA1 (0.74) | ADORA3ADORA1ADORA2AADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476169-B1 | Inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | claimed |
| EP-1476169-A4 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | claimed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | claimed |
| EP-1355916-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | claimed |
| CN-1267446-C | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO INC (US) | 2006-08-02 | — | — | CN | claimed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | claimed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | claimed |
| EP-1355916-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | claimed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | claimed |
| WO-2002057287-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885ADORA2A 416/4885 |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | ADORA3 649/4885ADORA1 735/4885ADORA2A 1134/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | ADORA3 464/4885ADORA1 539/4885ADORA2A 813/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885ADORA2A 416/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885ADORA2A 416/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | ADORA3 4434/4885ADORA1 4354/4885ADORA2A 4584/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | ADORA3 4434/4885ADORA1 4354/4885ADORA2A 4584/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA3 334/4885ADORA1 550/4885ADORA2A 416/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA3 225/4885ADORA1 238/4885ADORA2A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.